Under Rs 100: Aluminium Pharma Foils Manufacturer Reports 99.76 Per cent Growth in Monthly Sales in July; Stock Hits Upper Circuit Today!
The company’s shares have delivered an impressive return of around 100 per cent to its shareholders.
GSM Foils Limited, which specializes in the manufacturing of blister foils and aluminium pharma foils for pharmaceutical packaging, offers products ranging from 20 to 40 microns in thickness, suitable for coated, poly-laminated, blister, and printed foils.
The company’s stock hit the upper circuit today after updating its monthly sales volume. According to the company's latest announcement, their sales volume for July 2024 reached Rs 9,09,00,525 compared to Rs 4,55,04,836 representing a growth of 99.76 per cent. Net Sales for April-July 2024 stands at Rs 30,08,55,028.
Today, the shares of GSM Foils Limited hit the upper circuit and currently, they are at around Rs 65.65 per share on the NSE. The company’s current market capitalization stands at Rs 84.11 crore.
The company’s IPO launched in the month of May 2024 at Rs 32 each with a face value of Rs 10 each. The promoter holding pre-IPO was 99.99 per cent which is now reduced to 73.14 per cent after the IPO.
The company operates a 7,973-square-foot manufacturing facility located in the Sapphire Building in Thane, Vasai, Maharashtra. This ground-plus three-floor facility is fully equipped to handle all aspects of the production process, including seamless manufacturing, quality testing, research, storage, and packaging. In terms of revenue distribution, blister foils contribute 63 per cent of the company's revenue, while pharma foils account for the remaining 37 per cent. Geographically, the company has a strong presence across India, serving clients in 13 states and one Union Territory.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.
Check out my recent article here.
Investors must keep this stock on their radar.
Disclaimer: The article is for informational purposes only and not investment advice.